1. Home
  2. CYCU vs ACXP Comparison

CYCU vs ACXP Comparison

Compare CYCU & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cycurion Inc.

CYCU

Cycurion Inc.

HOLD

Current Price

$0.63

Market Cap

7.3M

Sector

N/A

ML Signal

HOLD

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.47

Market Cap

6.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYCU
ACXP
Founded
2017
2017
Country
United States
United States
Employees
74
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
6.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CYCU
ACXP
Price
$0.63
$1.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$7.00
$95.50
AVG Volume (30 Days)
602.4K
71.4K
Earning Date
06-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.92
N/A
Revenue Next Year
$10.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.29
52 Week High
$7.13
$8.34

Technical Indicators

Market Signals
Indicator
CYCU
ACXP
Relative Strength Index (RSI) 34.56 26.79
Support Level $0.58 $1.37
Resistance Level $1.05 $1.75
Average True Range (ATR) 0.07 0.11
MACD -0.01 0.00
Stochastic Oscillator 10.58 0.00

Price Performance

Historical Comparison
CYCU
ACXP

About CYCU Cycurion Inc.

Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: